OOIR: Observatory of International Research

Papers

(The H4-Index of AIDS is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Safety and efficacy of switching to 4-weekly albuvirtide plus daily dolutegravir in virologically suppressed HIV-1 adults: a 24-week study	130
Factors influencing antiretroviral therapy switching in people with virologically suppressed HIV-1: a cross-sectional multicenter study in France	86
Incidence and risk factors for recurrent sexually transmitted infections among MSM on HIV pre-exposure prophylaxis	82
From pregnancy to beyond: renewed emphasis on comprehensive HIV prevention in South Africa	76
Women with HIV: increased need for reproductive health services to improve health outcomes	66
Psychosocial factors account for a proportion of the difference in cognitive performance between persons with and without HIV	66
Body weight changes in people with HIV starting dolutegravir versus efavirenz-based regimens in a large cohort in rural Tanzania	58
Mitochondrial dysfunction in people with HIV receiving contemporary antiretroviral therapy	40
High-level dolutegravir resistance can emerge rapidly from few variants and spread by recombination: implications for INSTI salvage therapy	39
Cognitive function and mortality among persons aging with HIV and injection drug use	38
Analysis of HIV transmission characteristics and intervention effects in Guangxi based on molecular networks	38
A genetic variation in Fucosyltransferase 8 accelerates HIV-1 disease progression indicating a role for N-glycan fucosylation	37
A randomized clinical trial of on-demand oral pre-exposure prophylaxis does not modulate lymphoid/myeloid HIV target cell density in the foreskin	37
Risk factors and prognostic significance of anemia in children with HIV infection on antiretroviral therapy	36
Amebic liver abscess presenting in a nonendemic region after a 12-year latency in a patient with well controlled HIV infection	36
The potential impact of new tuberculosis vaccines on the burden of tuberculosis in people with HIV in South Africa	29
Bone density changes in young women in Uganda using tenofovir-based HIV preexposure prophylaxis and depot medroxyprogesterone acetate contraception	29
Strategies for managing weight gain associated with antiretroviral therapy: switch or add?	29
Epicardial fat and liver stiffness by acoustic radiation force impulse elastography in people with HIV-1 infection without liver disease	29
Plasma anti-CD4 IgG levels are not associated with poor immune recovery in people with HIV initiating antiretroviral therapy	27
The need to avert emergent resistance to dolutegravir in children and adolescents with HIV	27
Beyond virologic suppression	26
Long-term persistence of transcriptionally-active “defective” HIV-1 proviruses: Implications for persistent immune activation during antiretroviral therapy	26
T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa	26
HIV viral suppression in children and adolescents 2 years after transition to dolutegravir: a multicentre cohort study	25

Gestational weight gain in persons with HIV in the United States